Eli Lilly sees 2026 profit above estimates on weight‑loss drug demand

Eli Lilly Stock Jumps on Strong Earnings. Weight-Loss Drugs Have Something to Do With It.

Eli Lilly reports fourth-quarter earnings and revenue that handily top expectations and issues solid guidance.

Eli Lilly sees 2026 profit above estimates as demand for weight‑loss drugs soars

Eli Lilly forecast 2026 profit above Wall Street estimates on Wednesday, betting on surging demand for its obesity drugs as the world's most valuable drugmaker prepares to launch its oral weight-loss pill later this year.

Lilly Sees Surging Sales in Break From Weight Loss Rival Novo

Eli Lilly & Co. provided an upbeat sales forecast for the year Wednesday as strong demand for its weight loss drug cemented its position at the top of the obesity market.

Lilly reports fourth-quarter 2025 financial results and provides 2026 guidance

Revenue in Q4 2025 increased 43% to $19.3 billion driven by volume growth from Mounjaro and Zepbound. Q4 2025 EPS increased by 51% to $7.39 on a reported basis...